...Amarin's arguments against patent loss for its fish oil derivative drug Vascepa. A federal appeals court in September upheld a lower court ruling that definitively invalidates the patent, meaning generic challengers, including Hikma Pharmaceuticals, can move forward. Amarin had blockbuster hopes for the heart drug, which the FDA approved in December 2019. Vascepa currently holds preferred status for 33% of all covered lives under the pharmacy benefit, growing to 52% with utilization management restrictions. The drug holds covered or better status for 94% of all insured lives.
SOURCE: MMIT Analytics, as of 6/23/21
No comments:
Post a Comment